RecruitingPhase 3NCT05823311

Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Intervention
Lenvatinib, tislelizumab, gemcitabine and cisplatin(drug)
Enrollment
80 target
Eligibility
18-75 years · All sexes
Timeline
20232027

Study locations (1)

Collaborators

The First Affiliated Hospital of Zhengzhou University · The Affiliated Tumor Hospital of Xinjiang Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05823311 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials